



POSTER SESSION LOCATIONS AND SCHEDULE

2ND FLOOR - One Poster Room is located on the Meeting Floor Royall Room



1ST FLOOR - Remaining Poster Session Rooms are one floor down Peebles Room & Harris/Dowd Room



VIEWING TIMES

Poster Session	Date	Viewing Times
Session 1	Monday, May 16th	11:00am - 12:00pm
Session 2	Monday, May 16th	3:00pm - 4:00pm
Session 3	Tuesday, May 17th	11:00am - 12:00pm
Session 4	Tuesday, May 17th	3:00pm - 4:00pm

SET/STRIKE INFORMATION

Poster Session	Set Information	Strike Information
Session 1	May 15th 5pm - 8pm May 16th after 7am	All posters must be removed by 12:45pm on May 16th
Session 2	May 16th after 12:45pm	All posters must be removed by 6:15pm on May 16th
Session 3	May 16th 6:30pm - 8pm May 17th after 7am	All posters must be removed by 12:45pm on May 17th
Session 4	May 17th after 12:45pm	All posters must be removed by 4:30pm on May 17th

Poster Sessions

POSTER SESSION 1: MONDAY, MAY 16TH

11:00AM – 12:00PM

LOWER LEVEL: HARRIS/DOWD AND PEEBLES

No.	Title	Presenting Author
H1	End Stage Renal Disease (ESRD) in small vessel vasculitis: does ANCA serotype play a role?	Aladdin Mohammed, Lund, Sweden
H2	Prevalence of ANCA Associated Vasculitis and Polyarteritis Nodosa in Southern Sweden-Revisited 2010	Aladdin Mohammed, Lund, Sweden
H3	Clinical characteristics of patients with ANCA associated systemic vasculitis in South China: a study of 552 cases from a single center	Nan Chen, Shanghai, China
H4	Wegener's granulomatosis (WG) presentation according to anti-neutrophil cytoplasm antibody (ANCA) status: data from the French Vasculitis Society Group (FVSG) Database	Benjamin Terrier, Paris, France
H5	Improved outcome in ANCA associated renal vasculitis: a 30 year prospective study	Marc Hilhorst, Maastricht, The Netherlands
H6	An 11-year epidemiological study of Primary Systemic Vasculitis (PSV) in an area of northern Italy: Can vasculitic-ENT (ear, nose, throat) involvement aid diagnosis, therapy and prognosis?	Maria Santostefano, Ravenna, Italy
H7	Difference in clinical feature between MPO- and PR3-ANCA-positive Wegener's granulomatosis	Yoshinori Komagata, Tokyo, Japan
H8	Are there differences between ANCA negative and ANCA positive Pauci-immune glomerulonephritis? A 13 year single center experience	John Havill, Baltimore, MD, USA
H9	Prevalence of Alpha 1 Antitrypsin deficiency (AATD) in a cohort of ANCA-associated vasculitis (AAV) patients	Christina Avgoustinaki, Brescia, Italy
H10	Phagocytosis of apoptotic cells by macrophages in ANCA Associated Systemic Vasculitis (AASV)	Susanne Ohlsson, Lund, Sweden
H12	Cardiac involvement in Wegener's granulomatosis and Churg-Strauss syndrome	Tomaz Miszalski-Jamka, Krakow, Poland
H13	Thrombo-embolic disease in systemic vasculitis is associated with an enhanced microparticle mediated thrombin generation	Despina Eleftheriou, London, UK
H14	Four cases of MPO-ANCA positive vasculitis with hearing loss, and reviews of previous literatures	Nobuyuki Ono, Miyazaki, Japan
H15	Comparison of the epidemiology of anti-neutrophil cytoplasm antibody (ANCA) - associated vasculitis between Japan and UK	Shouichi Fujimoto, Miyazaki, Japan
H16	Dutch Transplantation in Vasculitis (DUTRAVAS)-study: A multi-center study on the outcome of renal transplantation in ANCA-associated vasculitis patients	Arda Goceroglu, Leiden, The Netherlands
H17	Prognostic Value of Repeated Renal Biopsy in ANCA-Associated Renal Vasculitis	Zdenka Hruskova, Prague, Czech Republic
H18	Epidemiologic and clinical features of Churg-Strauss Syndrome in Japan: a nation-wide survey in 2008	Ken-ei Sada, Okayama, Japan
H20	Monocyte Chemoattractant Protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis	Sophie Ohlsson, Lund, Sweden
H19	Cytomegalovirus colitis in a patient receiving corticosteroids for giant cell arteritis	John McLaren, United Kingdom
H20	Fatal medium vessel vasculitis presenting with anterior uveitis and membranous nephropathy	John McLaren, United Kingdom
P1	Profile of serum pro-inflammatory versus anti-inflammatory cytokine and their correlation with disease activity in Takayasu Arteritis	Debashish Danda, Vellore, India
P2	TNF- α Polymorphism in Takayasu's Arteritis - A preliminary study from tertiary centre in South India	Debashish Danda, Vellore, India
P3	A novel anti-neutrophil antibody in serum of patients with MPO-ANCA associated vasculitis	Koya Suzuki, Chiba, Japan
P4	IgA-ANCA in Wegener's granulomatosis (WG)	Darlene Nelson, Rochester, MN, USA
P5	Evidence for persistent endothelial injury years after Kawasaki Disease	Paul Brogan, London, UK
P6	Comparison of sensitivity of new pediatric Wegener's granulomatosis classification criteria with ACR and sorsensen criteria in an adult cohort	Burak Erer, Istanbul, Turkey
P7	Using color doppler ultrasound in Giant Cell Arteritis: Experience from an outpatient clinic	Andreas Diamantopoulos, Norway, Sweden
P8	Color Doppler Ultrasound as a follow up tool in large vessel vasculitis: Report of 5 cases.	Andreas Diamantopoulos, Norway, Sweden
P9	Is ITAS Index superior to DEI-Tak for the assessment of disease activity in Takayasu's Arteritis?	Neslihan Yilmaz, Istanbul, Turkey
P10	Clinical Utility of Erythrocyte Sedimentation Rate and C-Reactive Protein in Diagnosis of Biopsy-Positive Giant Cell Arteritis	Tanaz Kermani, Rochester, MN, USA
P11	Soluble ST2 levels are elevated in patients with ANCA-associated systemic vasculitis at diagnosis regardless of the presence of lung involvement	Zdenka Hruskova, Prague, Czech Republic

POSTER SESSION 1: MONDAY, MAY 16TH

11:00AM – 12:00PM
UPPER LEVEL - ROYALL

No.	Title	Presenting Author
R1	Identification of target antigens of anti-smooth muscle cell antibodies in patients with ANCA-associated systemic vasculitis: a proteomic approach	Alexis Regent, Paris, France
R2	Characterization of the pathogenic potential of ANCA at disease onset, relapse and remission	Aleeza Roth, Chapel Hill, NC, USA
R3	Increased expression of histone H3 lysine 27 demethylases in ANCA vasculitis patients	Kerry Colby, Chapel Hill, NC, USA
R4	The PTPN22 gain-of-function SNP results in ERK inhibition leading to down-regulation of IL-10 mRNA expression in ANCA-vasculitis	Jiajin Yang, Chapel Hill, NC, USA
R5	Post-catalytic myeloperoxidase is more accessible than pre-catalytic myeloperoxidase for the binding of anti-myeloperoxidase antibodies	Peng-Cheng Xu, Beijing, China
R7	Cytochrome P450 Polymorphism as a predictor of adverse effects and therapy response in patients with ANCA-associated vasculitis (AAV)	Birgit Buhl, Groningen, The Netherlands
R8	Genetic Variant in Uridine Diphosphate Glucuronosyltransferase (UGT) and Small Vessel Vasculitis	Melanie Joy, Chapel Hill, NC, USA
R9	Molecular characterisation of Pseudomonas aeruginosa isolates from Cystic fibrosis patients with and without BPI-ANCA	Swati Shukla, Lund, Sweden
R10	Delineating Wegener's Granulomatosis, Microscopic Polyangitis and Churg-Strauss Syndrome: Genetic risk factors associated with a positive ANCA status	Julia Holle, Bad Bramstedt, Germany
R11	The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients	Huan Luo, Beijing, China
R12	A genome wide association study in ANCA-associated vasculitis	Sapna Trivedi, Cambridge, UK

Poster Sessions

POSTER SESSION 2: MONDAY, MAY 16TH

3:00PM – 4:00PM

LOWER LEVEL: HARRIS/DOWD AND PEEBLES

No.	Title	Presenting Author
H1	Relapses in Wegener's granulomatosis and monthly PR3-ANCA values in 9 different solid phase assays	Anna Salmela, Finland
H2	Effect of IVIg monotherapy on "cytokine and chemokine storm" in acute phase of MPO-ANCA positive microscopic polyangiitis(MPA)	Eri Muso, Osaka, Japan
H3	Soluble fms-like tyrosine kinase 1 (sFLT) is elevated in ANCA associated vasculitis and declines during therapy	Svetlana Lovric, Hannover, Germany
H4	Circulating Markers of Vascular Injury and Angiogenesis in ANCA-associated Vasculitis	Paul Monach, Boston, MA, USA
H5	Circulating NET remnants in ANCA associated vasculitis (AASV)	Daina Selga, Lund, Sweden
H6	Sensitive assessment of activity of Takayasu's arteritis by Pentraxin3, a new biomarker	Takashi Ishihara, Tokyo, Japan
H7	Hepcidin levels in patients with ANCA-associated vasculitis	Pavel Konopasek, Praha, Czech Republic
P7	Alcoholism is an important trigger for the development of Henoch-Schonlein Purpura	Matthias Schaier, Heidelberg, Germany
H8	Serum Biomarkers in Giant Cell Arteritis	Kenneth Warrington, Rochester, MN, USA
H9	Two Types of Proteinase-3 ANCA Affinity of Wegener's Granulomatosis in Small Vessel Vasculitis	Masaharu Yoshida, Tokyo, Japan
H10	Anti-PR3 and anti-MPO antibodies are not present in tuberculosis, leprosy or leishmaniasis	Isabella Lima, Nazare, Brazil
H11	ANCA-testing by high sensitive methods in ANCA-associated systemic vasculitis (AASV) diagnosis	Antonella Radice, Milan, Italy
H12	Comparative evaluation of a novel high sensitive, fully automated method for MPO-ANCA detection (EliA MPOS), in diagnosis of ANCA-associated systemic vasculitis (AASV)	Antonella Radice, Milan, Italy
H13	Comparative Evaluation of anti-PR3, anti-MPO, and anti-GBM EIA Assays for the Detection of ANCA and Antibodies to GBM	Wen Kumpfert, Hercules, CA, USA
H14	Sensitivity Analysis of Multimodality ANCA Testing under Controlled Conditions	Ulrich Specks, Rochester, MN, USA
H17	Multiplex Planar Microarray Assay for Simultaneous Detection of Autoantibodies for ANCA-associated Vasculitis and Anti-GBM-associated Glomerulonephritis	Jeff Terryberry, Ontario, Canada
H18	Method Comparison of Multiplex Planar Microarray and Enzyme-linked Immunoassay for Detection ANCA-associated Vasculitis PR3 and MPO Autoantibodies.	Jeff Terryberry, Ontario, Canada
H19	Performance evaluation of novel chemiluminescence assay for detections of anti-GBM antibodies: An International multi-center study	Michael Mahler, San Diego, CA, USA
P1	"I'm too worn out to go anywhere with anyone": The Impact of Vasculitis on Patients' Social Participation	Amy Meador, Chapel Hill, NC, USA
P2	Dimensions of fatigue in ANCA associated vasculitis (AAV): Level of physical activity is associated with less fatigue, but not to age of disease onset or duration	Birgit Buhl, Groningen, The Netherlands
P3	Predictors of medication non-adherence for vasculitis patients: From demographic factors to interpersonal influences	Delesha Carpenter, Chapel Hill, NC, USA
P4	What influences vasculitis patients' perceptions of physician credibility: The importance of physician behavior	Emily Elstad, Chapel Hill, NC, USA
P5	What do people with Wegener's Granulomatosis want to know about their illness?	Janice Mooney, Norwich, UK
P6	Quality of Life, Disability and Depression in Takayasu's Arteritis	Neslihan Yilmaz, Istanbul, Turkey

POSTER SESSION 2: MONDAY, MAY 16TH3:00PM – 4:00PM
UPPER LEVEL - ROYALL

No.	Title	Presenting Author
R1	Influenza Vaccination and The Development Of Anti-Neutrophil Cytoplasmic Antibodies: In Vitro Findings	Lisa Jeffs, Adelaide, Australia
R2	LAMP-2 autoantibodies are not prevalent in an Eastern US cohort of patients with antineutrophil cytoplasmic autoantibody (ANCA) glomerulonephritis	Aleeza Roth, Chapel Hill, NC, USA
R3	Increased plasma levels of CXCL1 and CCL20 reflecting Th17 activity active Wegener's granulomatosis and microscopic polyangiitis	Per Eriksson, Linköping, Sweden
R4	Characterization of B cell subsets and role of regulatory B cells in ANCA production in patients with ANCA-associated vasculitis	Nikola Lapse, Groningen, The Netherlands
R5	Characterization of autoreactive B lymphocytes from Wegener's granuloma through single cell analysis and generation of recombinant antibodies	Jan Voswinkel, Paris, France
R6	Decreased numbers and defective innate function of circulating dendritic cells subsets in ANCA-associated vasculitis	Marie Rimbart, Nantes, France
R6	Comparison of characteristics of natural autoantibodies to myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis	Peng-Cheng Xu, Beijing, China
R7	Patients with ANCA-associated vasculitis in long-term remission have increased numbers of circulating IL-10 producing Th17 cells	Benjamin Wilde, Maastricht, The Netherlands
R8	Clues for a Possible Role of Senescent T Cells in Giant Cell Arteritis Pathogenesis	Kornelis Stephen Mario van der Geest, Groningen, The Netherlands
R9	Interleukin 15 and ANCA-associated vasculitis (AAV)	Birgit Buhl, Groningen, The Netherlands
R10	Increased circulating FoxP3+ T-cells in WG-patients are attributed to an increase in the non-suppressor FoxP3Low CD45RO+ TReg cell subpopulation	Wayel Abdulahad, Groningen, The Netherlands
R11	Increase frequency of circulating Follicular helper T-cells (Tfh) in patients with Wegener's granulomatosis	Wayel Abdulahad, Groningen, The Netherlands
R12	IgA ANCA from patients with Erythema Elevatum Diutinum activate neutrophils in vitro	Matthew Morgan, Birmingham, UK

Poster Sessions

POSTER SESSION 3: TUESDAY, MAY 17TH

11:00AM – 12:00PM

LOWER LEVEL: HARRIS/DOWD AND PEEBLES

No.	Title	Presenting Author
H1	Treatment of Orbital Inflammation with Rituximab in Wegener's Granulomatosis	Bo Baslund, Copenhagen, Denmark
H2	Rituximab (RTX) for Wegener granulomatosis (WG): Clinical observations in a heterogeneous population With predominant granulomatous disease	Luis Felipe Flores-Suarez, Mexico City, Mexico
H3	Rituximab as rescue therapy in ANCA associated systemic vasculitis: a single centre experience	Paul Gatenby, Woden, Australia
H4	Maintenance therapy with low doses steroid and methotrexate or azathioprine to prolong the efficacy of rituximab course	Guido Jeannin, Brescia, Italy
H5	Protocolised versus non-protocolised rituximab treatment for refractory ANCA-associated vasculitis	Rachel Jones, Cambridge, UK
H6	Repeat treatment with Rituximab remains effective over multiple courses in ANCA associated vasculitis	Matthew Morgan, Birmingham, UK
H7	Continuous Rituximab Therapy for ANCA Associated Vasculitis	John Niles, Boston, MA, USA
H8	Long term follow-up of Refractory Systemic Vasculitis treated with Rituximab (RTX)	Frances Rees, Nottingham, UK
H9	Infections related mortality during induction of remission in ANCA associated vasculitis (AAV) can be reduced by less toxic immunosuppressive induction treatment	Elisabeth Krarup, Herlev, Denmark
H10	Hypogammaglobulinaemia and infections following Rituximab therapy for system vasculitis and systemic lupus erythematosus (SLE)	Helena Marco, Cambridge, UK
H11	A Comparison of Two International Multi-Centre Surveys of Plasma Exchange Practices in ANCA Associated Vasculitis	Alina Casian, Cambridge, UK
H12	Plasmapheresis rescue therapy in progressive ANCA-associated systemic vasculitis	A.A.E de Joode, Groningen, The Netherlands
H13	Low cyclophosphamide (CYC) dose and plasma exchange (PLEX) a less toxic induction treatment of ANCA associated vasculitis (AAV)	Wladimir Szpirt, Copenhagen, Denmark
H14	Renal outcomes in patients presenting with dialysis dependant ANCA associated vasculitis treated with pulsed intravenous cyclophosphamide	Ruth Pepper, London, UK
H15	A Randomized Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Induction Therapy in ANCA Associated Systemic Vasculitis with renal involvement	Nan Chen, Shanghai, China
H16	Application of RIFLE criteria in Chinese patients with ANCA associated renal vasculitis	Nan Chen, Shanghai, China
H17	ANCA associated vasculitis and pulmonary hemorrhage	Nishkantha Arulkumaran, London, UK
H18	MPO-ANCA associated vasculitis with pulmonary fibrosis	Nishkantha Arulkumaran, London, UK
H19	Airway stenosis in Wegener's granulomatosis – Cambridge experience	Marcos Martinez Del Pero, Cambridge, UK
H20	Validation of a disease activity scoring system for the assessment of ENT complaints in Wegener's granulomatosis	Marcos Martinez Del Pero, Cambridge, UK
P1	Efficacy and tolerance of TNFalpha antagonists in Takayasu disease	Arsene Mekinian, Bondy, France
P2	Randomized controlled open labelled prospective comparative study of effect of statins in patients with Takayasu	Sankaralingam Rajeswari, India
P3	First prospective trial in Japanese patients with MPO-ANCA-associated vasculitis	Shoichi Ozaki, Kawasaki, Japan
P4	ANCA-associated systemic vasculitis/rapidly progressive glomerulonephritis in Japan: clinical features and pronostic changes	Kunihiro Yamagata, Ibaraki, Japan
P5	Baseline data and interim induction analysis based on 101 patients >65 years old with systemic necrotizing vasculitides(SNV) enrolled in the CORTAGE multicenter trial	Christian Pagnoux, Paris, France
P6	Value of Anti-Neutrophil Cytoplasmic Antibody (ANCA) Measurements during Remission to Predict a Relapse of ANCA-Associated Vasculitis: A meta-Analysis	Gunnar Tomasson, Boston, MA, USA
P7	Development and use of an index to assess disease-related damage in Takayasu Arteritis (TADS)	Sivakumar Rajappa, Chennai, India
P8	Renal Transplantation in ANCA associated vasculitis: Allograft Outcome and Vasculitis Relapse Rate	Duvuru Geetha, Baltimore, MD, USA

2011

POSTER SESSION 3: TUESDAY, MAY 17TH11:00AM – 12:00PM
UPPER LEVEL - ROYALL

No.	Title	Presenting Author
R1	The protective role of NADPH oxidase in ANCA-induced vasculitis	Adrian Schreiber, Berlin, Germany
R2	In situ-immune complex (MPO-anti MPO antibody) relates to glomerular capillary injury in human-MPO-ANCA associated glomerulonephritis	Soko Kawashima, Tokyo, Japan
R3	Synergistic relation of Podocytes and Glomerular Endothelium during inflammatory episodes of Vasculitic Glomerulonephritis - Recapitulation of Glomerular micro environment	Sahithi Panchagnula, Birmingham, UK
R4	Macrophage migration inhibitory factor (MIF) in ANCA-associated vasculitis	Annette Bruchfeld, Stockholm, Sweden
R5	IL-32 as a driver of chronic inflammation in Wegener's granuloma?	Sebastian Jendrek, Luebeck, Germany
R6	Increased expression of hypoxia-inducible factor 1 and glucose transporter-1 in nasal mucosa from patients with Wegener's Granulomatosis – a new perspective on hypoxic signalling in granulomatous lesions	Nina Kesel, Hamburg, Germany
R7	Decreased CXCR1 and CXCR2 expression on neutrophils in ANCA-associated vasculitis increases neutrophil adhesion and impairs transendothelial migration	Nan Hu, Groningen, The Netherlands
R8	Neutrophil LL-37 promotes rapid sensing of CpG DNA by B-lymphocytes and plasmacytoid dendritic cells	Chen Au Peh, Adelaide, Australia
R9	Wegener's Granulomatosis: Possible Role of LL-37 in granuloma formation	Plinio Reinaldo Hurtado, Adelaide, Australia
R10	Aberrant neutrophils in the pathogenesis of ANCA-Associated Systemic Vasculitis	Mohamed Abdgawad, Lund, Sweden
R11	ANCA, through the activation of PI3K and MTOR, promote neutrophil exocytosis in vitro	Neil Holden, Birmingham, UK
R12	Potential role of TLR-induced PMN activation in the triggering of disease activity in Wegener's granulomatosis	Julia Holle, Bad Bramstedt, Germany

Poster Sessions

POSTER SESSION 4: TUESDAY, MAY 17TH

3:00PM – 4:00PM

LOWER LEVEL: HARRIS/DOWD AND PEEBLES

No.	Title	Presenting Author
H1	Comparison of CNS vasculitis in Children and Adults; is this the same disease entity	Marinka Twilt, Ontario, Canada
H2	Granulomatous Angitis of the Central Nervous System and Cerebral Amyloid: Vasculitis or Vasculopathy	Daniel Albert, Lebanon, NH, USA
H3	Severe deterioration of vasculitis in a patient with Takayasu arteritis treated interferon beta-1a due to concomitant multiple sclerosis	Andreas Diamantopoulos, Norway, Sweden
H4	Disease assessment in Takayasu's Arteritis: data from a literature search and survey of expert opinion	Haner Direskeneli, Istanbul, Turkey
H5	Association Between Vascular Physical Examination Findings and Arteriographic Lesions in Subjects with Large Vessel Vasculitis	Peter Grayson, Boston, MA, USA
H7	Peripheral neuropathy in ANCA-associated vasculitis	Ravi Suppiah, Headington, UK
H8	Predicting cardiovascular events in patients with newly diagnosed ANCA-associated vasculitis	Ravi Suppiah, Headington, UK
H9	The prognostic value of BVAS and VDI in ANCA-associated vasculitis	Ravi Suppiah, Headington, UK
H10	Th17 cells in Wegener granulomatosis	Anna Sediva, Prague, Czech Republic
H11	Lung nodules in Behcet Disease (BD)	Luis Felipe Flores-Suarez, Mexico City, Mexico
H12	Unilateral multiple cranial nerve palsy in Wegener granulomatosis (WG)	Luis Felipe Flores-Suarez, Mexico City, Mexico
H13	Wegener Granulomatosis (WG) and CD4+ Lymphocytopenia: Case Report and Implications for Rituximab (RTX) Therapy	Luis Felipe Flores-Suarez, Mexico City, Mexico
H14	Giant cell arteritis (GCA) and disseminated tuberculosis (TB)	Luis Felipe Flores-Suarez, Mexico City, Mexico
H15	Initial presentation of colon cancer as relapsing pulmonary small vessel ANCA-negative vasculitis	Patricia Fanlo, Pamplona, Spain
H16	Successful management of polyarteritis nodosa presenting with catastrophic gastrointestinal involvement with pneumatis intestinalis	Patricia Fanlo, Pamplona, Spain
H17	Small-vessel vasculitis associated with Mycoplasma pneumoniae infection; report of three cases	Patricia Fanlo, Pamplona, Spain
H18	Necrotizing sarcoid granulomatosis with pulmonary and esophageal involvement	Zuzana Rihova, Brussels, Belgium
H19	An unusual neurological manifestation of Wegener's Granulomatosis	Rona Smith, Cambridge, UK
H20	IL-1 blockade for Schnitzler's Syndrome	Rona Smith, Cambridge, UK
P1	ANCA-negative Vasculitis: A study of 24 cases	Nan Chen, Shanghai, China
P2	Analyzing fatal cases of Chinese patients with primary antineutrophil cytoplasmic antibodies associated renal vasculitis	Nan Chen, Shanghai, China
P3	Anemia in ANCA-associated vasculitis	Michael Kraft, Munchen, Germany
P4	Disease activity, damage and survival analysis of Wegener's granulomatosis: Long term single center experience from Turkey	Sevil Kamali, Istanbul, Turkey
P5	Wegener's Granulomatosis: clinical features and outcome in Brazilian patients	Luciener DaSilva, Brazil
P6	The registry of patients with primary systemic vasculitis – experience of a single referral center in southern Poland	Jan Sznajd, Krakow, Poland
P7	Fat pulmonary embolism: A rare cause of diffused intra alveolar hemorrhage – 2 case reports	Daniele Avanzi, Brescia, Italy
P8	Vasculitis Overlap Syndromes: Hickam's dictum vs. Occam's razor	Duvuru Geetha, Baltimore, MD, USA
P8	Alveolar Hemorrhage in ANCA associated vasculitis: an analysis of EUVAS Trials	Alina Casian, Cambridge, UK
P9	Relapsing leukocytoclastic vasculitis associated with lupus-related cryoglobulinemia during pregnancy	Carlos Perez, Pamplona, Spain
P10	Successful treatment with rituximab in a refractory Wegener's granulomatosis with leukoencephalopathy and pachymeningitis	Carlos Perez, Pamplona, Spain
P11	Eicosapentanoic acid-induced remission of ANCA vasculitis in a case with cardiovascular risk	Junichi Hirahashi, Tokyo, Japan

2011

POSTER SESSION 4: TUESDAY, MAY 17TH3:00PM – 4:00PM
UPPER LEVEL - ROYALL

No.	Title	Presenting Author
R1	Microparticle Tissue Factor Activity is a Novel Indicator of Disease Activity in Patients with PR3-ANCA Vasculitis	Madelyn Burkart, Chapel Hill, NC, USA
R2	Correlation between platelet aggregation and/or circulating microparticles and disease activity in Wegener's granulomatosis	Rula Hajj-Ali, Cleveland, USA
R3	Elevated active secretory acid sphingomyelinase activity in ANCA associated vasculitis	Allan Kiprianos, Birmingham, UK
R4	Major differences among proteomes of macro-vascular and micro-vascular endothelial	Hanadi Dib, Paris, France
R5	Impaired vasculogenic function of endothelial progenitor cells in children with primary systemic vasculitis	Ying Hong, London, UK
R6	Direct activation of glomerular endothelial cells in anti-moesin activity of anti-myeloperoxidase antibody	Tomokazu Nagao, Chiba, Japan
R7	Treatments for MPO-ANCA-associated vasculitis in SCG/Kj mouse	Reina Kusunoki, Chiba, Japan
R8	Remission, relapse and renal scarring in Experimental Autoimmune Vasculitis	Mark Little, London, UK
R9	Identification of target antigens of anti-endothelial-cell and anti-vascular-smooth-muscle-cell antibodies in patients with giant cell arteritis : a proteomic approach	Alexis Regent, Paris, France
R10	Multiple ANCA specificities in MRL/lpr Mice	Donglai Ma, Ontario, Canada
R11	MPO-ANCA epitopes in SCG/Kj mice	Kazuo Tomizawa, Tokyo, Japan
R12	Monoclonal antibodies against myeloperoxidase induce crescentic glomerulonephritis in mice	Mirjan Van Timmeren, Groningen, The Netherlands


Exhibitors

Genentech	101
Takeda	102
Immuno-Biological Laboratories, Inc (IBL America)	103
Inova Diagnostics, Inc.	104
EUROIMMUN US LLC	105
Questcor Pharmaceuticals	106
Vasculitis Foundation	108
Pfizer	109